SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

HiberGene Diagnostics Ltd.. (4/12/17). "Press Release: HiberGene Closes €6.7m Series B Funding Round". Dublin.

Organisations Organisation HiberGene Diagnostics Ltd.
  Organisation 2 Cantor Fitzgerald & Co.
  Group Cantor Fitzgerald (Group)
Product Product  venture capital
Index term Index term HiberGene–SEVERAL: investment, 201504–201704 financing round Series B €6.7m led by Cantor Fitzgerald
Persons Person Farrell, Brendan (HiberGene 201704 CEO)
  Person 2 Stephenson, Tony (Exitus Communications 201503)

Hibergene Diagnostics, a company focussed on applying molecular technology to the infectious disease segment of the diagnostics market, has closed a Series B Funding Round of €6.7m.

The Series B Round was led by Cantor Fitzgerald with Hibergene’s Series A Investors also participating in this round, including Kernel Capital, through the Bank of Ireland Kernel Capital Venture Funds. Further funding was provided through MedCaptain, Hibergene’s distributor for China. EIS investment in UK was advised by Ruffena Capital Ltd resulting in UK based investors subscribing for shares via the SyndicateRoom investment platform.

The new funds will be used to expand Hibergene’s R&D programmes, with a number of new products planned for launch in 2017. To date, Hibergene has launched five products. These include HG Meningococcus, HG Group B Streptococcus, HG C. Difficile, Strepelle and the HG Swift platform. The company also has products in development for Mycoplasma Pneumoniae, Flu A/B and RSV 1/2, and these will be launched in 2017.

In addition, the company will accelerate the expansion of its international distributor network. Hibergene currently has 24 distributors covering 36 countries, across Europe, Asia, the Middle East and Africa, and this will be expanded to cover additional territories including North and South America.

Brendan Farrell, CEO of HiberGene, said: “We are grateful to our investors for providing the funding which will enable Hibergene to significantly expand both its range of diagnostic products and its global reach. With its excellent portfolio of products capable of rapidly and accurately diagnosing infectious diseases, coupled with a growing network of distributors and end-users, Hibergene is well placed to become a global provider of unique and innovative diagnostic products.”


For more information, please contact:

Tony Stephenson
Exitus Communications
Tel: +44 (0)7899 796655

Brendan Farrell
Chairman & CEO
HiberGene Diagnostics Limited

Notes to Editors:

About HiberGene

HiberGene is a diagnostics company focussed on applying molecular technology to the infectious disease segment of the diagnostic market. Utilising the LAMP platform, HiberGene has developed rapid and highly sensitive diagnostic tests for Meningococcus, Group B Streptococcus and C. difficile which can be used in almost any clinical or laboratory setting. HiberGene intends to continue to expand its test menu for the detection of human infectious diseases.

Record changed: 2017-04-18


Picture [LSUS] – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

» top